**Name of Journal: *World Journal of Transplantation***

**ESPS Manuscript NO: 24035**

**Manuscript Type: Original Article**

***Retrospective Study***

**Higher plasma bilirubin predicts veno-occlusive disease in early childhood undergoing** [**hematopoietic stem cell transplantation**](http://www.ncbi.nlm.nih.gov/pubmed/25260979) **with cyclosporine**

Kim KS *et al.* Biliburin predicts VOD in childhood HSCT

**Kwi Suk Kim, Aree Moon, Hyoung Jin Kang, Hee Young Shin, Young Hee Choi, Hyang Sook Kim, Sang Geon Kim**

**Kwi Suk Kim, Hyang Sook Kim,** Department of Pharmacy, Seoul National University Hospital, Seoul 03080, South Korea

**Aree Moon,** College of Pharmacy, Duksung Women’s University, Seoul 01369, South Korea

**Hyoung Jin Kang, Hee Young Shin,** Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea

**Young Hee Choi,** College of Pharmacy, Dongguk University, Goyang, Gyeonggi-do 410-820, South Korea

**Sang Geon Kim,** College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 03080, South Korea

**Sang Geon Kim,** Department of Pharmacy, Seoul National University Hospital, Seoul 03080, South Korea

**Author contributions:** Kim KS, Moon A and Kim SG for conception and design of the study; Kim KS, Choi YH and Kim SG for analysis and interpretation; Kim KS and Kim HS for data collection; Kim KS, Choi YH and Kim SG for writing the article; Kang HJ for critical revision of the article; Kim KS, Shin HY and Kim SG for final approval of the article; Kim KS and Choi YH for statistical analysis; Kim KS and Kim SG for overall responsibility.

**Supported by** The Education and Research Encouragement Fund of Seoul National University Hospital.

**Institutional review board statement:** This study was approved by the Institutional Review Board of Seoul National University Hospital (SNUH; H-1112-087-390, 2012.3.17), a 1961-bed medical center, on March 17, 2012.

**Informed consent statement:** The authors petition BPG for waiver of informed consent because this study was not a clinical trial, but was retrospectively done using anonymized electronic medical records of the study subjects. In addition, authors declared that the study subjects were at no risk due to this study.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Sang Geon Kim, PhD, Professor,** College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 101 Daehak-ro Jongno-gu, Seoul 03080, South Korea. sgk@snu.ac.kr.

**Telephone:** +82-2-8807840

**Fax:** +82-2-8807840

**Received:** January 2, 2016

**Peer-review started:** January 3, 2016

**First decision:** February 2, 2016

**Revised:** February 22, 2016

**Accepted:** March 17, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To analyze the association between plasma bilirubin levels and veno-occlusive disease (VOD) in non-adult patients undergoing hematopoietic stem cell transplantation(HSCT) during cyclosporine therapy.

**METHODS:** A total of 123 patients taking cyclosporine were evaluated using an electronic medical system at the Seoul National University Children’s Hospital from the years 2004 through 2011. Patients were grouped by age and analyzed for incidence and type of adverse drug reactions (ADRs) including VOD.

**RESULTS:** The HSCT patients were divided into three age groups: G#1 ≥ 18; 9 ≤ G#2 < 17; and G#3 ≤ 8 years of age). The majority of transplant donor types were cord blood transplantations. Most prevalent ADRs represented acute graft-versus-host disease (aGVHD) and VOD. Although the incidences of aGVHD did not vary among the groups, the higher frequency ratios of VOD in G#3 suggested that an age of 8 or younger is a risk factor for developing VOD in HSCT patients. After cyclosporine therapy, the trough plasma concentrations of cyclosporine were lower in G#3 than in G#1, indicative of its increased clearance. Moreover, in G#3 only, a maximal total bilirubin level (BILmax) of ≥ 1.4 mg/dL correlated with VOD incidence after cyclosporine therapy.

**CONCLUSION:** HSCT patients 8 years of age or younger are more at risk for developing VOD, diagnosed as hyperbilirubinemia, tender hepatomegaly, and ascites/weight gain after cyclosporine therapy, which may be represented by a criterion of plasma BILmax being ≥ 1.4 mg/dL, suggestive of more sensitive VOD indication in this age group.

**Key words:** Cyclosporine; Hematopoietic stem cell transplantation; Veno-occlusive disease; Adverse drug reaction; Total bilirubin

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study analyzed the association between plasma bilirubin and veno-occlusive disease (VOD) in childhood undergoing hematopoietic stem cell transplantation(HSCT) during cyclosporine therapy. Here, we report that age of 8 or under may be a risk factor for VOD in CsA-treated patients who underwent HSCT with differential clearance of CsA*.* Another finding is that a criterion of 1.4 mg/dL of plasma maximal total bilirubin level or higher content alone closely represents the incidence of VOD in early childhood patients with HSCT in CsA therapy. Information shown in this study would be of great help to understand VOD occurring during CsA medication and to find optimal pharmacotherapy in HSCT patients.

Kim KS, Moon A, Kang HJ, Shin HY, Choi YH, Kim HS, Kim SG. Higher plasma bilirubin predicts veno-occlusive disease in early childhood undergoing [hematopoietic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/25260979) with cyclosporine. *World J Transplant* 2016; In press

**INTRODUCTION**

Cyclosporine is a major immunosuppressant for organ transplantation, and is widely used for the prophylactic treatment of acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation (HSCT)[1]. However, the morbidity and mortality resulting from acute, or subsequently following chronic GVHD, and veno-occlusive disease (VOD), as indicated by hyperbilirubinemia, tender hepatomegaly, and ascites, are obstacles to the use of cyclosporine alone or in combination with other agents[2]. Clinical studies on cyclosporine therapy demonstrated differences between neonate, child and adult populations in the incidence of adverse drug reactions (ADRs)[3]. Since these events are closely linked to the metabolic burden and/or clearance of the drug, ADRs should be monitored and avoided depending on the types of transplantation, age groups and pharmacokinetic profiles. In particular, the dose regimens and therapeutic concentrations need to be appropriately adjusted for optimal efficacy and/or minimized ADRs.

Cyclosporine therapy should be carefully monitored as a therapeutic drug monitoring (TDM) system[4]. Monitoring of pharmacokinetic profiles, including oral bioavailability, has been claimed in the context of successful pharmacotherapy because intestinal absorption of cyclosporine varies depending on the type of transplantation, age, and other parameters of patients[5-9]. In general, patients of a young age seem to be more at risk for ADRs to cyclosporine, and exhibit different ADR profiles[10]. Therefore, the oral dose of cyclosporine required for the maintenance of therapeutic blood levels is significantly augmented in childhood patients[5]. In addition to the narrow therapeutic range of cyclosporine, the types and incidences of cyclosporine-induced ADRs vary depending on the types and severities of diseases, as well as patient age[11].

It has been recognized that wide variations exist in the plasma concentrations of cyclosporine among HSCT patients[12].A limited number of studies have been performed in cyclosporine-treated neonates and children who underwent HSCT in the context of ADR monitoring[13]. In Seoul National University Hospital, the administered dose of cyclosporine was equally determined by the post-surgical day of HSCT, which frequently resulted in cyclosporine plasma concentrations being out of therapeutic range (150-250 ng/mL). Although the normalized doses of cyclosporine for transplant patients of childhood age were usually higher than those for adults, the plasma concentrations were significantly lower[3]. This raised the contention that biotransformation and/or excretion of cyclosporine is accelerated in childhood patients, which may be linked to ADRs, such as GVHD, nephrotoxicity, and neurotoxicity[13].

Age-different effects of cyclosporine therapy on the types and incidences of ADRs in HSCT patients are known[14-16]. Nevertheless, more sensitive indicator(s) would be of great help to avoid or minimize serious ADRs and to accomplish successful pharmacotherapy, especially in patients of the childhood population who would be more prone to drug-induced harmful effects. This study analyzed the association between plasma bilirubin levels and VOD in non-adult patients undergoing HSCT during cyclosporine therapy. Here, we report that marginally high levels of total plasma bilirubin reliably indicate VOD during cyclosporine therapy in the HSCT patient of early childhood.

**MATERIALS AND METHODS**

***Datasets***

This study was approved by the Institutional Review Board of Seoul National University Hospital (SNUH; H-1112-087-390, 2012.3.17), a 1961-bed medical center, on March 17, 2012. The data collected had anonymous codes representing patient files comprising the following medical information: Age, gender, medical diagnosis codes, date of HSCT, absolute neutrophil count (ANC), post-transplantation day, donor types (cord blood and related donor), body weight, body surface area, body temperature, types of ADRs, peak and trough concentrations of cyclosporine, serum hematocrit, ALT (alanine aminotransferase), AST (aspartate aminotransferase), serum total bilirubin levels, dates of labs drawn, medications (generic and brand name, prescription date), and duration of chemotherapeutic agent along with co-prescribed drugs.

***Patients***

The database contained records of 123 patients (ages ranging from 2 to 24 with 68 males and 55 females) who had been hospitalized in SNUH from September 15, 2004 to December 31, 2012 and had undergone measurements of plasma cyclosporine levels using a radioimmunoassay kit. Cyclosporine concentrations were monitored on day 1, 4, 11 18, 24, and 28 after HSCT and at intervals of three or seven days after day 28 of HSCT in SNUH. Laboratory data were obtained from 123 patients, with three of them having HSCTs twice in this period. The total number of cyclosporine measurements was 2149, with an average of 17.5 measurements per patient.

HSCT patients who had been administered cyclosporine were divided into three groups based on age: G#1, 18 years of age or older; G#2, between 9 and 17 years of age; and G#3, 8 years of age or under. The median ages in G#1, G#2, and G#3 were 20, 13 and 6, respectively. Each group was additionally split into four subgroups by the levels of BILmax [*i.e.*, BILmax (-), lower than 1.4 mg/dL of total plasma bilirubin; and BILmax (+), 1.4 mg/dL of total plasma bilirubin or higher] and VOD incidence [*i.e*., VOD (-), no existing VOD; and VOD (+), existing VOD].

***Statistical analysis***

The Fisher exact test was chosen to determine differences in the frequency of BILmax ≥ 1.4 mg/dL between VOD (-) and VOD (+) groups. Multivariate analysis was performed to find risk factors for drug therapy. Data represent the median (0.5-24.0 mg/dL). Results were considered statistically significant if the P-value was less than 0.05. Statistical analyses were conducted using the Duncan and Fisher’s tests in SPSS Version 12.0 (SPSS Inc., Chicago, IL, United States).

**RESULTS**

The characteristics of HSCT patients treated with cyclosporine (*n* = 123) are summarized in Table 1. Of the patients examined, cord blood transplantation constituted the majority of the transplant donor type (G#1, 60%; G#2, 58.6%; and G#3, 75.0%). The most prevalent ADR event observed was aGVHD (G#1, 61.9%; G#2, 46.4%; and G#3, 54.2%), whereas the second most frequent ADR event was VOD (9.5%-29.2%). Although the incidences of aGVHD, diagnosed as cytopenia and delayed immune reconstitution, did not vary much between the groups, the frequency ratios of VOD were significantly higher in G#3. Thus, being 8 years of age or under at the time of transplantation would be a possible risk factor for VOD in patients who underwent HSCT from cord blood donors. In types of diseases, ALL and AML highly occurs in all three groups of patients, but there was no significant difference of the disease incidence rate depending on the age. Also the liver functions (*i.e*., ALT and AST activities) were comparable in all groups of patients.

After intravenous administration, the trough plasma concentrations of cyclosporine were significantly lower (83.8% and 62.2% in G#2 and G#3, respectively, versus G#1) in G#2 or G#3 than in G#1, although the injected dose of cyclosporine was normalized to the patient body weight (Table 2). The trough plasma concentrations of cyclosporine were approximately 40% lower in G#3 than in G#1, indicative of its accelerated clearance in G#3. The trough plasma cyclosporine levels were similarly changed in the groups examined after oral administration; in this case, the oral dose was approximately 30% greater in G#3 than in G#1 (or G#2), suggesting the possibility that the bioavailability of cyclosporine was significantly lower in G#3 (Table 2). These results indicate that the clearance and/or turnover rate of cyclosporine in plasma might be augmented in G#3, whereas the oral bioavailability was lower in this group, implying the potential of increased detoxifying burden in the patients presumably due to accelerated biotransformation and excretion of cyclosporine.

Given the distinct difference in plasma cyclosporine concentrations and the potential of increased cyclosporine clearance in G#3, we next asked whether the incidences of VOD statistically correlated with total bilirubin levels in plasma among the patients examined. Setting the BILmax cutoff level at 2.0 mg/dL demonstrated an obvious increment in VOD incidences in high BILmax groups when G#2, G#3 or the total population was analyzed, although it failed in demonstrating increased VOD incidences when G#1 was solely analyzed (data not shown). More importantly, setting the BILmax cutoff level at 1.4 mg/dL (a minimal significant value obtained empirically) revealed an augmented incidence of VOD in the high BILmax group in G#3 (*P* < 0.0001), but not in G#1 or G#2, as determined by two-by-two analyses (Table 3).

**DISCUSSION**

ADR-related admissions are a problem with a high prevalence[17,18]. Menendez-Conde *et al*[18] reported thatMenéndez-CondeMenéndez-Conde Menéndez-Con19.4% of admissions were direct consequences of ADRs, 65% of which were preventable[19]. In particular, cyclosporine therapy causes various ADRs (*e.g.*, 20% of infectious complications during the therapy and 5% of severe GVHD)[20,21], with approximately 6% of admissions eliciting permanent damage, including seizures or death[22]. In general, the dose of cyclosporine is calculated for transplant patients primarily on the basis of body weight[23]. However, this approach has limitations, such as the development of aGVHD, cGVHD, hepatotoxicity, gastrointestinal disorders, infections and hemorrhagic cystitis[24]. Large variations in plasma cyclosporine concentrations exist in individuals (*i.e.*, 5-8 fold differences)[25]. Since the biotransformation capacities of endogenous and exogenous substances vary depending on the stage of development and maturation, attention should be directed to cyclosporine clearance. The results of this study demonstrated the impact of age differences on the incidence and type of ADRs during cyclosporine therapy in HSCT patients of early childhood as compared to adolescent patients.

A major advantage of HSCT is the potential for therapeutic benefits from graft-versus-leukemia effects, which are mediated by donor T and natural killer cells[26]. Unfortunately, graft-versus-leukemia effects are closely linked to aGVHD as the major limiting toxicity of allogeneic transplantation, which causes damage to the skin, gastrointestinal tract, and liver[27]. Studies have shown that aGVHD frequently occurred when plasma concentrations of cyclosporine decreased to 125-200 ng/mL 12 h after treatment[25,28]. Depletion of T cells from the graft effectively prevented aGVHD, but it also limited graft-versus-leukemia effects, possibly increasing the rate of graft failure[29]. Therefore, plasma concentrations of immunosuppressant are currently one of the critical factors to maintain the proper balance between aGVHD and graft-versus-leukemia effects. The lowest plasma cyclosporine concentration (< 200 ng/mL) in the third week after transplantation showed a high risk factor related to aGVHD (grades II-IV) in HSCT patients[30]. Thus, assessment of cyclosporine levels is a valuable diagnostic tool to predict aGVHD. In the present study, we observed that the incidences of aGVHD (*i.e.*, cytopenia and delayed immune reconstitution) were not much different among the groups examined, which supports the appropriateness of the pharmacotherapy.

Patients currently meet McDonald’s VOD-Seattle Criteria by exhibiting two or more of the following criteria: Hyperbilirubinemia > 2 mg/dL, tender hepatomegaly, and either ascites or weight gain (> 2%). A key finding of this study is that VOD occurrences were significantly higher in G#3. Similarly, the incidences of VOD increased in childhood age[31], whereas VOD was frequently observed day 18 (the median) after intravenous administration of cyclosporine[32]. When we compared the plasma levels of cyclosporine and other pharmacokinetic parameters, the turnover rate of cyclosporine seemed to vary in different age groups. Our finding showing lower plasma cyclosporine level with higher occurrence of VOD in G#3 differs from the previous report that high plasma concentrations or high doses of drugs in pediatric HSCT patients related to the frequent and severe VOD in different therapy in HSCT patients[33]. VOD occurrence seems to be associated with clearance of endogenous compounds as well as cyclosporine[34]. It has also been suggested that the clearance rate of cyclosporine may affect VOD and total bilirubin levels in blood[34]. This idea is consistent with the finding that the pharmacokinetic profile of cyclosporine was characterized by substantially faster elimination in children compared to adults, which necessitated more frequent dosing intervals and higher doses for younger children[7,35]. So, low plasma cyclosporine levels in G#3 may reflect its high turnover rate. Overall, our results and others support the contention that the turnover rate of cyclosporine is increased, particularly in HSCT patients of early childhood.

Our finding that HSCT patients of 8 years of age or under were more at risk for the reactions of VOD, which was distinctively characterized by the plasma BILmax level being ≥ 1.4 mg/dL, indicates that plasma BILmax alone may serve as a valuable marker of VOD in this particular patient population. Since a large fraction of cyclosporine binds with erythrocytes (41%-50%)[36], cyclosporine-induced hyperbilirubinemia may result from destabilization and/or disruption of red blood cell membranes, with the consequent release of heme for biodegradation and excretion. It has also been shown that the clearance of red blood cells was slower, whereas the maturity and differentiation of red blood cells were lower in children compared to other groups[37]. Disruption of canaliculi in children has also been shown to increase, even at lower cyclosporine concentrations[38]. Therefore, the frequency of splenomegaly increases presumably due to the clearance of damaged red blood cells and debris, along with heme disposal, resulting in the subsequent production of bilirubin[39]. Consistently, red blood cells may be impaired after cyclosporine therapy, especially during radiation therapy[40].

Since cyclosporine is mainly oxidized viaCYP3A4, followed by glucuronide conjugation via UGT1A1 and UGT2B7, total bilirubin levels in the blood would increase, enhancing the burden of detoxification[41]. Cyclosporine is primarily metabolized by CYP3A4 in the liver, 95% of which is excreted via the biliary route. The main reason for the low bioavailability of cyclosporine may be due to its extensive intestinal metabolism by CYPs[42]. The various rate and extent of cyclosporine metabolism, depending on age and drug interactions (60%-90%), may be related with polymorphisms of CYP3A4[43]. The genetic associations between UGT variations and cyclosporine pharmacokinetics in patients would also affect its efficacy and ADRs (*e.g*., GVHD, hepatic and/or gastrointestinal disorders) presumably due to unpredictable cyclosporine concentrations[44]. Our results showed that plasma cyclosporine levels were significantly lower in G#3 despite the highest normalized dose. Clearance of endogenous bilirubin might also be reduced in the patients presumably due to relatively low rate of metabolism. Thus, cyclosporine biotransformation may change depending on the metabolic clearance of bilirubin, which would increase in early childhood compared to adolescents and/or adults[45]. Alterations in red blood cell turnover and/or interference of biliary excretion of glucuronidated cyclosporine would also contribute to total plasma bilirubin levels[46].

The value of pharmacist-provided drug-monitoring care to transplant recipients has been recognized as a beneficial service[47]. Considering the complexity of pharmacotherapy, pharmacists need to implement clinically relevant interventions on the transplant unit[48]. Although the dangers of ADRs are well recognized by clinicians and pharmacists, the efforts to elucidate the basis of ADRs still exist in clinical fields[49]. This situation stimulated attempts to validate ways of ADR monitoring by developing new and critical indicators, algorithms and analytical tools[50,51]. HSCT patients represent a population at high risk for drug-related problems[52]. Our results demonstrate that HSCT patients 8 years of age or under are at higher risk for developing the reactions of VOD after cyclosporine therapy, which may be indicated by plasma BILmax levels being ≥ 1.4 mg/dL, suggesting that this new criterion alone may be used as an indicator of VOD during cyclosporine therapy in HSCT patients of young childhood. A guideline for ADR-related problems and interventions may aid staffs working in the HSCT unit to optimize pharmaceutical care of patients, thereby reducing economic costs resulting from inappropriate drug utilization.

**COMMENTS**

***Background***

The incidence of veno-occlusive disease (VOD) differs from the ages of childhood, which is an obstacle of the use of cyclosporine, immunosuppressant for organ transplantation. Especially, the VOD incidence was higher in cyclosporine-treated neonates and children who underwent hematopoietic stem cell transplantation(HSCT). Therefore, the authors analyzed the association between plasma bilirubin levels and VOD in childhood patients undergoing HSCT during cyclosporine therapy.

***Research frontiers***

The sensitive indicator(s) would be of great help to avoid or minimize serious VOD and to accomplish successful cyclosporine therapy, especially in patients of the childhood population with higher VOD incidence. The results of this study contribute to clarifying the associations of bilirubin, VOD and cyclosporine concentrations.

***Innovations and breakthroughs***

Although age-different effects of cyclosporine therapy on various adverse drug reactions in HSCP patients are existing, the association between plasma bilirubin levels and VOD in non-adult patients undergoing HSCT during cyclosporine therapy was not reported yet. Thus, the authors report that marginally high levels of total plasma bilirubin reliably indicate VOD during cyclosporine therapy in the HSCT patient of early childhood.

***Applications***

A plasma BILmax levels being ≥ 1.4 mg/dL may be used as an indicator of VOD during cyclosporine therapy in HSCT patients of young childhood. A guideline for ADR-related problems and interventions may aid staffs working in the HSCT unit to optimize pharmaceutical care of patients, thereby reducing economic costs resulting from inappropriate drug utilization.

***Terminology***

BILmax (-): Lower than 1.4 mg/dL of total bilirubin during cyclosporine therapy; BILmax (+): 1.4 mg/dL of total plasma bilirubin or higher during cyclosporine therapy.

***Peer-review***

This review is well written, presenting a very significant issue of “an increased risk for developing VOD after cyclosporine treatments in younger (< 8 years old) generations”. Authors also claimed that the plasma BILmax levels being ≥ 1.4 mg/dL would provide a useful indicator to recognize the development of VOD in those generations.

**REFERENCES**

1 [**Umeda K**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Umeda%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Adachi S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Adachi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Tanaka S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Tanaka%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Ogawa A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ogawa%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Hatakeyama N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hatakeyama%20N%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Kudo K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kudo%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Sakata N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sakata%20N%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Igarashi S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Igarashi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Ohshima K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ohshima%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Hyakuna N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hyakuna%20N%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Chin M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Goto H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Goto%20H%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Takahashi Y](http://www.ncbi.nlm.nih.gov/pubmed/?term=Takahashi%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Azuma E](http://www.ncbi.nlm.nih.gov/pubmed/?term=Azuma%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Koh K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Koh%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Sawada A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sawada%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Kato K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kato%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Inoue M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Inoue%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Atsuta Y](http://www.ncbi.nlm.nih.gov/pubmed/?term=Atsuta%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Takami A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Takami%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25307105), [Murata M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Murata%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25307105); [on behalf of the GVHD Working Group of the Japan Society for Hematopoietic CellTransplantation](http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20GVHD%20Working%20Group%20of%20the%20Japan%20Society%20for%20Hematopoietic%20Cell%20Transplantation%5BCorporate%20Author%5D). Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. *Pediatr Blood Cancer* 2014 [PMID: 25307105 DOI: 10.1002/pbc.25243]

2 **Chao NJ**, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. *N Engl J Med* 1993; **329**: 1225-1230 [PMID: 8413388 DOI: 10.1056/NEJM199310213291703]

3 **Neiberger R**, Weiss R, Gomez M, Greifer I, Tellis VA, Matas AJ. Elimination kinetics of cyclosporine following oral administration to children with renal transplants. *Transplant Proc* 1987; **19**: 1525 [PMID: 3274371]

4 **Kahan BD**, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. *Clin Ther* 2002; **24**: 330-350; discussion 329 [PMID: 11952020 DOI: 10.1016/S0149-2918(02)85038-X]

5 **Burckart GJ**, Venkataramanan R, Ptachcinski RJ, Starzl TE, Gartner JC, Zitelli BJ, Malatack JJ, Shaw BW, Iwatsuki S, Van Thiel DH. Cyclosporine absorption following orthotopic liver transplantation. *J Clin Pharmacol* 1986; **26**: 647-651 [PMID: 3540030 DOI: 10.1002/j.1552-4604.1986.tb02966.x]

6 **Willemze AJ**, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J, Vossen JM. Ciclosporin kinetics in children after stem cell transplantation. *Br J Clin Pharmacol* 2008; **66**: 539-545 [PMID: 18492124 DOI: 10.1111/j.1365-2125.2008.03217.x]

7 **Yee GC**, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. *Clin Pharmacol Ther* 1986; **40**: 438-443 [PMID: 3530588 DOI: 10.1038/clpt.1986.204]

8 **Yee GC**, McGuire TR, Gmur DJ, Lennon TP, Deeg HJ. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit. *Transplantation* 1988; **46**: 399-402 [PMID: 3047931 DOI: 10.1097/00007890-198809000-00012]

9 **Crocker JFS**, Dempsey T, Schenk ME, Renton KW. Cyclosporine A toxicity in children. *Transplantation Reviews* 1993; **7**: 72-81 [DOI: 10.1016/S0955-470X(05)80041-2]

10 **Yaffe SJ**, Aranda JV. eds. Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice; Lippincott Williams & Wilkins, 2010: 896-904

11 **Ingulli E**, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children--a single-center experience. *Transplantation* 1991; **51**: 401-405 [PMID: 1994534 DOI: 10.1097/00007890-199102000-00025]

12 **Wilhelm AJ**, de Graaf P, Veldkamp AI, Janssen JJ, Huijgens PC, Swart EL. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. *Br J Clin Pharmacol* 2012; **73**: 553-563 [PMID: 21988410 DOI: 10.1111/j.1365-2125.2011.04116.x]

13 **Fabiano V**, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. *Expert Opin Drug Saf* 2012; **11**: 95-105 [PMID: 21548838 DOI: 10.1517/14740338.2011.584531]

14 **FDA Product Information**. Sandimmune® oral capsules, oral solution, intravenous injection. [updated 2013 Mar]. Available from: URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm319403.htm

15 **Scheinberg P**, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. *J Pediatr* 2008; **153**: 814-819 [PMID: 18672253 DOI: 10.1016/j.jpeds.2008.06.004]

16 **Balci YI**, Tavil B, Karabulut E, Kuskonmaz B, Kucukbayrak O, Akyol F, Hascelik G, Cetin M, Uckan D. Cyclosporine level at the second hour in pediatric hematopoietic stem cell transplant patients. *Exp Clin Transplant* 2011; **9**: 329-335 [PMID: 21967260]

17 **Bordet R**, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. *Eur J Clin Pharmacol* 2001; **56**: 935-941 [PMID: 11317484 DOI: 10.1007/s002280000260]

18 **Pérez Menéndez-Conde C**, Bermejo Vicedo T, Delgado Silveira E, Carretero Accame E. Adverse drug reactions which provoke hospital admission. *Farm Hosp* 2011; **35**: 236-243 [PMID: 21570331 DOI: 10.1016/j.farma.2010.08.003]

19 **Muehlberger N**, Schneeweiss S, Hasford J. Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. *Pharmacoepidemiol Drug Saf* 1997; **6** Suppl 3: S71-S77 [PMID: 15073757 DOI: 10.1002/(SICI)1099-1557(199710)6: 3]

20 **Berger R**, Avramoff A, Leiba M, Domb AJ, Laor A, Nagler A. Cyclosporine safety and bioavailability with two second-generation softgel capsules using serum concentrations/TDM and modeling in transplant patients--a retrospective, parallel, comparative evaluation study. *Int J Clin Pharmacol Ther* 2008; **46**: 165-171 [PMID: 18397689 DOI: 10.5414/CPP46165]

21 **Bleyzac N**. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. *Fundam Clin Pharmacol* 2008; **22**: 605-608 [PMID: 19049662 DOI: 10.1111/j.1472-8206.2008.00652.x]

22 **Zhong ZD**, Li L, Wu YH, You Y, Li WM, Zou P. Analysis of seizure risk factors after allogeneic hematopoietic stem cell transplantation: a 8 case report and literature review. *J Huazhong Univ Sci Technolog Med Sci* 2013; **33**: 656-660 [PMID: 24142716 DOI: 10.1007/s11596-013-1176-x]

23 **Bock HA**, Kamber V, Brunner FP, Thiel G. Weight-independent dosing of cyclosporine--an alternative to the "mg/kg" doctrine. *Transplantation* 1994; **57**: 1484-1489 [PMID: 8197612 DOI: 10.1097/00007890-199405000-00015]

24 **Styczyński J**, Debski R, Krenska A, Wysocki M. [Efficacy and toxicity of intravenous busulfan-based conditioning treatment before hAematopoietic stem cell transplantation in children: preliminary report]. *Med Wieku Rozwoj* 2008; **12**: 1098-1104 [PMID: 19531833]

25 **Lindholm A**. Therapeutic monitoring of cyclosporin--an update. *Eur J Clin Pharmacol* 1991; **41**: 273-283 [PMID: 1804639 DOI: 10.1007/BF00314952]

26 **Mosaad YM**. Immunology of hematopoietic stem cell transplant. *Immunol Invest* 2014; **43**: 858-887 [PMID: 25296239 DOI: 10.3109/08820139.2014.942460]

27 **Sung AD**, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. *Stem Cells Transl Med* 2013; **2**: 25-32 [PMID: 23283494 DOI: 10.5966/sctm.2012-0115]

28 **Moyer TP**, Johnson P, Faynor SM, Sterioff S. Cyclosporine: a review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. *Clin Biochem* 1986; **19**: 83-89 [PMID: 3518993 DOI: 10.1016/S0009-9120(86)80053-4]

29 **Ho VT**, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. *Blood* 2001; **98**: 3192-3204 [PMID: 11719354 DOI: 10.1182/blood.V98.12.3192]

30 **Zeighami S**, Hadjibabaie M, Ashouri A, Sarayani A, Khoee SH, Mousavi S, Radfar M, Ghavamzadeh A. Assessment of cyclosporine serum concentrations on the incidence of acute graft versus host disease post hematopoietic stem cell transplantation. *Iran J Pharm Res* 2014; **13**: 305-312 [PMID: 24734085]

31 **Cesaro S**, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, Strugo L, Destro R, Gazzola MV, Varotto S, Errigo G, Carli M, Zanesco L, Messina C. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. *Haematologica* 2005; **90**: 1396-1404 [PMID: 16219577]

32 **Cheuk DK**, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, Chan GC. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007; **40**: 935-944 [PMID: 17768390 DOI: 10.1038/sj.bmt.1705835]

33 **Bearman SI**. The syndrome of hepatic veno-occlusive disease after marrow transplantation. *Blood* 1995; **85**: 3005-3020 [PMID: 7756636]

34 **Myers KC**, Lawrence J, Marsh RA, Davies SM, Jodele S. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients. *Biol Blood Marrow Transplant* 2013; **19**: 500-503 [PMID: 23211838 DOI: 10.1016/j.bbmt.2012.11.011]

35 **Whitington PF**, Emond JC, Whitington SH, Broelsch CE, Baker AL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. *N Engl J Med* 1990; **322**: 733-738 [PMID: 2308602 DOI: 10.1056/NEJM199003153221105]

36 **McMillan MA**. Clinical pharmacokinetics of cyclosporin. *Pharmacol Ther* 1989; **42**: 135-156 [PMID: 2657807 DOI: 10.1016/0163-7258(89)90025-9]

37 **McCance KL**, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 7th ed. 2014: 982-1007

38 **Román ID**, Coleman R. Disruption of canalicular function in isolated rat hepatocyte couplets caused by cyclosporin A. *Biochem Pharmacol* 1994; **48**: 2181-2188 [PMID: 7811299 DOI: 10.1016/0006-2952(94)90352-2]

39 **Kildey K**, Flower RL, Tran TV, Tunningley R, Harris J, Dean MM. Characterization of ENU-induced Mutations in Red Blood Cell Structural Proteins. *Comput Struct Biotechnol J* 2013; **6**: e201303012 [PMID: 24688720 DOI: 10.5936/csbj.201303012]

40 **Anand AJ**, Dzik WH, Imam A, Sadrzadeh SM. Radiation-induced red cell damage: role of reactive oxygen species. *Transfusion* 1997; **37**: 160-165 [PMID: 9051090 DOI: 10.1046/j.1537-2995.1997.37297203518.x]

41 **Strassburg CP**, Barut A, Obermayer-Straub P, Li Q, Nguyen N, Tukey RH, Manns MP. Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. *J Hepatol* 2001; **34**: 865-872 [PMID: 11451170 DOI: 10.1016/S0168-8278(01)00040-X]

42 **Leather HL**. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. *Bone Marrow Transplant* 2004; **33**: 137-152 [PMID: 14676788 DOI: 10.1038/sj.bmt.1704316]

43 **Flockhart DA**, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. *Pharmacogenomics J* 2003; **3**: 3-5 [PMID: 12629575 DOI: 10.1038/sj.tpj.6500144]

44 **Dupuis R**, Yuen A, Innocenti F. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. *Clin Chim Acta* 2012; **413**: 1318-1325 [PMID: 22327003 DOI: 10.1016/j.cca.2012.01.031]

45 **Ginsberg G**, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. *Toxicol Sci* 2002; **66**: 185-200 [PMID: 11896285 DOI: 10.1093/toxsci/66.2.185]

46 **Levitt DG**, Levitt MD. Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease. *Clin Exp Gastroenterol* 2014; **7**: 307-328 [PMID: 25214800 DOI: 10.2147/CEG.S64283]

47 **Chisholm-Burns MA**, Spivey CA, Garrett C, McGinty H, Mulloy LL. Impact of clinical pharmacy services on renal transplant recipients' adherence and outcomes. *Patient Prefer Adherence* 2008; **2**: 287-292 [PMID: 19920975 DOI: 10.2147/PPA.S4174]

48 **Slattery JT**, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. *Ther Drug Monit* 1998; **20**: 543-549 [PMID: 9780133 DOI: 10.1097/00007691-199810000-00017]

49 **Repp KL**, Hayes C, Woods TM, Allen KB, Kennedy K, Borkon MA. Drug-related problems and hospital admissions in cardiac transplant recipients. *Ann Pharmacother* 2012; **46**: 1299-1307 [PMID: 23032656 DOI: 10.1345/aph.1R094]

50 **Chiang AP**, Butte AJ. Data-driven methods to discover molecular determinants of serious adverse drug events. *Clin Pharmacol Ther* 2009; **85**: 259-268 [PMID: 19177064 DOI: 10.1038/clpt.2008.274]

51 **Suh DC**, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. *Ann Pharmacother* 2000; **34**: 1373-1379 [PMID: 11144691 DOI: 10.1345/aph.10094]

52 **Prot-Labarthe S**, Therrien R, Demanche C, Larocque D, Bussières JF. Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service. *J Oncol Pharm Pract* 2008; **14**: 147-152 [PMID: 18719069 DOI: 10.1177/1078155208093929]

**P-Reviewer:** Saeki K, Tanabe S, Zou ZM **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 The characteristics of hematopoietic stem cell transplantation patients treated with cyclosporine (*n* = 123)**

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | G#1 (*n* = 25) | G#2 (*n* = 70) | G#3 (*n* = 28) |
| Age (mean, SD) | 20.3, 1.7 | 13.0, 2.5 | 5.8, 2.2 |
| Initial Body Weight (mean, SD) | 51.8, 11.1 | 37.8, 12.7 | 14.0, 4.0 |
| Gender (M, %) | 15 (60.0) | 35 (50.0) | 17 (60.7) |
| Liver function (mean SD) |  |  |  |
| ALT (mg/dL)AST (mg/dL) | 67.6, 95.870.2, 73.1 | 67.1, 67.372.9, 61.5 | 104, 133161, 356 |
| Doner types (*n*, %)Cord bloodRelated donorTypes of disease (*n*, %)AAABLALLAMLCMLJMMLMDSOthersObserved events (*n*, %)aGVHDcGVHDVODDICRelapseEF | 15 (60.0)10 (40.0)5 (20.0)4 (16.0)10 (40.0)5 (20.0)0 (0.0)0 (0.0)1 (4.0)0 (0.0)13 (61.9)1 (4.8)2 (9.5)4 (19.0)1 (4.8)0 (0.0) | 41 (58.6)29 (41.4)6 (8.6)5 (7.1)28 (40.0)20 (28.6)2 (2.9)0 (0.0)2 (2.9)7 (10.0)26 (46.4)4 (7.1)13 (23.2)4 (7.2)2 (3.6)7 (12.5) | 21 (75.0)7 (25.0)1 (3.6)2 (7.1)7 (25.0)10 (35.7)0 (0.0)4 (14.3)1 (3.6)3 (10.7)13 (54.2)0 (0.0)7 (29.2)2 (8.3)1 (4.2)1 (4.2) |

Age groups: G#1, 18 years or older; G#2, 9 to 17 years old; G#3, 8 years old or under.

AA: Aplastic anemia; ABL: Acute biphenotypic leukemia; ALL: Acute lymphocytic leukemia; AML: Acute myelocytic leukemia; CML:Chronic myelocytic leukemia; JMML: Juvenile myelomonocytic leukemia; MDS: Myelo dysplastic syndromes; aGVHD: Acute graft versus host disease; cGVHD: Chronic graft versus host disease; VOD: Veno-occlusive disease; DIC: Disseminated intravascular coagulation; EF: Engraft failure.

**Table 2 Median trough plasma concentrations and doses of cyclosporine in hematopoietic stem cell transplantation patients**

|  |  |  |  |
| --- | --- | --- | --- |
| Contents | G#1 (*n* = 25) | G#2 (*n* = 70) | G#3 (*n* = 28) |
| IV | Trough plasma concentrationb (ng/mL) | 535.6 (264.0-1214.0)a | 448.9 (184.5-1070.0) | 333.1 (152.5-819.0 ) |
|  | Dose (mg/kg) | 5.8 (3.9-7.7) | 6.1 (3.5-14.2) | 6.0 (3.8-9.3) |
| PO | Trough plasma concentrationb (ng/mL) | 345.9 (166.0-686.5) | 247.7 (40.0-496.5) | 204.4 (33.0-302.5) |
|  | Dose (mg/kg)c | 8.2 (3.4-11.4) | 8. 2(1.6-17.5) | 10.6 (6.0-24.6) |

aThe values in parenthesis represent the minimum and maximum trough plasma concentrations of cyclosporine; bG#1 was significantly different from G#2 or G#3 using Duncan test; cG#3 was significantly different from G#1 or G#2 using Duncan test.

**Table 3 Two by two analyses between maximal plasma bilirubin contents and veno-occlusive disease in hematopoietic stem cell transplantation patients**

|  |  |  |  |
| --- | --- | --- | --- |
|  | G#1 (*n* = 25) | G#2 (*n* = 70) | G#3 (*n* = 28) |
|  | BILmax- | BILmax+ |  | BILmax- | BILmax+ |  | BILmax- | BILmax+ |
| VOD + | 0 | 2 |  | 4 | 9 |  | 0 | 7 |
| VOD - | 5 | 18 | 28 | 29 | 17 | 4 |
| *P-*value | 1.00 | 0.356 | 0.0001 |

BILmax+: 1.4 mg/dL or higher; BILmax -: Lower than 1.4 mg/dL. Data were analyzed using Fisher’s test program. BILmax: A maximal total bilirubin level; VOD: Veno-occlusive disease.